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Abstract
Background: Several techniques have been tailored to the quantification of microRNA expression, including
hybridization arrays, quantitative PCR (qPCR), and high-throughput sequencing. Each of these has certain strengths
and limitations depending both on the technology itself and the algorithm used to convert raw data into expression
estimates. Reliable quantification of microRNA expression is challenging in part due to the relatively low abundance
and short length of the miRNAs. While substantial research has been devoted to the development of methods to
quantify mRNA expression, relatively little effort has been spent on microRNA expression.
Results: In this work, we focus on the Life Technologies TaqMan OpenArray system, a qPCR-based platform to
measure microRNA expression. Several algorithms currently exist to estimate expression from the raw amplification
data produced by qPCR-based technologies. To assess and compare the performance of these methods, we
performed a set of dilution/mixture experiments to create a benchmark data set. We also developed a suite of
statistical assessments that evaluate many different aspects of performance: accuracy, precision, titration response,
number of complete features, limit of detection, and data quality. The benchmark data and software are freely
available via two R/Bioconductor packages,miRcomp andmiRcompData. Finally, we demonstrate use of our
software by comparing two widely used algorithms and providing assessments for four other algorithms.
Conclusions: Benchmark data sets and software are crucial tools for the assessment and comparison of competing
algorithms. We believe that themiRcomp andmiRcompData packages will facilitate the development of new
methodology for microRNA expression estimation.
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Background
MicroRNAs (miRNAs) are a class of small (18–24
nucleotide) regulatory RNAs. They are essential regula-
tors that act as translational repressors throughout many
eukaryotic species [1]. Several thousand miRNAs have
been described in humans and other species, although in
practicality only 350–400 are present at robust levels in
mature cells and tissues [2]. MiRNAs are known to alter
their expression levels in disease, malignancy, and cell
stress [3] and exhibit tissue and cell-type specific patterns
of expression [4, 5].
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Many expression platforms, originally designed to quan-
tify mRNA expression, have been adapted to globally
assay miRNA expression including hybridization arrays,
quantitative PCR (qPCR), and sequencing [6]. However,
each of these approaches must overcome several chal-
lenges specific to miRNAs: short sequence length, low
abundance of target molecules, and sequence homology
betweenmiRNAs. Comparative performance assessments
are crucial to understanding the strengths and limitations
of each approach to miRNA quantification. A group of
investigators recently systematically evaluated 12 available
miRNA platforms across 20 standardized control samples
[7]. This study, calledmiRQC, established metrics to assay
reproducibility, sensitivity, accuracy, specificity and con-
cordance across the different methods. Although a single
platform was not found to be uniformly superior, there
© 2016 McCall et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
McCall et al. BMC Bioinformatics  (2016) 17:138 Page 2 of 13
was substantial variability in performance across assess-
ments. For each of the platforms, performance depends
on both the instrument and the algorithm used to con-
vert raw measurements into expression estimates. For
example, one platform assessed in the miRQC study was
RNA-seq performed on an Illumina GAIIx instrument.
The sample prep used the TruSeq Small RNA Prep Kit
and results were aligned to the hg19 reference sequence
allowing one mismatch, without further delineation of the
alignmentmethod [7]. A previous performance evaluation
of miRNA expression arrays noted a strong dependency
between technology and signal processing methodology
[8]. More recently, we have demonstrated that different
miRNA RNA-seq alignment algorithms produce differ-
ent alignments, impacting the quality of the data [9]. We
surmise that many miRNA expression platforms are not
yet optimized to yield consistent and maximally accurate
data.
Another platform evaluated in the miRQC study was
the Life Technologies TaqMan OpenArray system. This
is a qPCR-based miRNA array platform that currently
has coverage for 754 human miRNAs across two sets of
primer pools. While qPCR is considered the gold stan-
dard for low-throughput measurement of gene expres-
sion, microarray- and sequencing-based platforms are
preferable for most high-throughput applications. Given
the relative small number of common miRNAs, it is
possible to use a qPCR-based platform to measure the
expression of all abundant miRNAs in many tissues
and cells.
The primary advantage of qPCR-based technologies is
the ability to simultaneously amplify and quantify a tar-
get transcript over sequential PCR cycles. The greater
the initial amount of the target transcript present in a
sample, the more rapidly the target will reach a thresh-
old at which it can be detected by flourescence (e.g.
from amplicon-associated intercalating dyes or freed,
unquenched hydrolysis probes). As such, the raw data
produced by qPCR-based technologies are fluorescence
signal intensities captured at the end of each amplifica-
tion cycle (typically 1–40). Analysis of these data typically
begins by assigning a threshold cycle number to each
amplification. These threshold cycles can then be used to
estimate target abundance, either relative or in reference
to values for a standard curve. For example, Life Technolo-
gies provides the ExpressionSuite software package, which
uses the shape of the amplification curve to estimate a rel-
ative threshold cycle and corresponding expression esti-
mate [10]. While a substantial number of software tools
have been developed to estimate gene expression from
raw amplification data [11–13], these focused on mRNA
rather than miRNA targets. Whether these methods per-
form similarly when estimating miRNA expression is an
area of ongoing research.
The software presented in this manuscript provides
tools to assess and compare the performance of methods
to transform raw amplification data into expression esti-
mates and determine optimal quality thresholds. While
the miRQC study focused on comparing many differ-
ent platforms, here we focus on a single platform but
provide a much larger and more diverse data set for eval-
uation. We believe that the availability of these data and
corresponding software will greatly accelerate the devel-
opment of improved methodology for the OpenArray
miRNA platform. Furthermore, seamless integration with
the R/Bioconductor [14, 15] suite of analysis packages will
enhance the value of OpenArray miRNA data. There-
fore, we developedmiRcomp, an R package to assess and
compare microRNA expression estimation methods using




Two separate RNA pools were prepared by blending two
tissues each: (1) kidney and placenta and (2) skeletal mus-
cle and brain (frontal cortex). These sources of RNA
were chosen based on our prior analysis of Agilent V3
miRNA array data that suggested this collection of tissues
would capture a large number of microRNAs, including
several unique to each sample, such as miR-133a for skele-
tal muscle and the chromosome 19 miRNA cluster for
placenta [2].
The surgical pathology archives of the Department of
Pathology at Johns Hopkins Hospital were used to obtain
formalin fixed paraffin-embedded (FFPE) tissues from
four distinct tissue sources. All tissues were verified as
normal by review of tissue histology on an adjacent hema-
toxylin and eosin stained slide. These anonymized human
samples were used based on an exemption from the Insti-
tutional Review Board of Johns Hopkins Hospital.
RNA extraction
We extracted RNA from FFPE sections of kidney, pla-
centa, skeletal muscle, and brain using the AllPrep
DNA/RNA FFPE protocol (Qiagen). Xylene was chosen
for deparaffinization. Extra xylene and ethanol washes
were performed, and DNase digestion was done on-
column.
RNA quality control
Concentration of eluted RNA was assessed by NanoDrop.
Due to the low quality of longer RNAmolecules extracted
from FFPE tissues, including the ribosomal RNAs, the
presence of several ubiquitous and tissue-enriched small
RNAs or miRNAs was confirmed by stem-loop reverse
transcription quantitative PCR using 10 ng RNA per reac-
tion. For example, miR-1 and miR-133a were enriched
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in skeletal muscle, miR-516b was enriched in placenta,
and miR-200b was enriched in kidney (Additional file 7:
Figure S1). RNA was stored at −80C.
Reverse transcription and pre-amplification
The kidney/placenta (KP) and skeletal muscle/brain (MB)
mixtures were made by combining equal masses of kidney
and placenta or skeletal muscle and frontal cortex RNA,
respectively, and diluting to an equal concentration of
3.3 ng/ul. 10 ng of RNA was used as the input for reverse
transcription using the A and B primer pools, following
the Life Technologies OpenArray protocol modification
for low-concentration and FFPE RNA. Separate reverse
transcription and pre-amplification reactions were per-
formed for the Life Technologies MegaPlex Pools A and
B primer pools, which reverse transcribe and pre-amplify
specific microRNAs. Following pre-amplification, 30 ul
from the A and B reactions for both KP and MB were
mixed with 570 ul of 0.1x TE. Further dilutions and
combinations of the KP and MB mixtures were then
prepared. To keep the non-nucelic acid components
equal after mixing KP and MB, we added a diluent C
mix as needed (Fig. 1). The diluent C included the same
proportions of RT buffer and Pre-Amp mix components
as in the Life Technologies protocol-specified dilution of
nucleic acid-containing post-pre-amp mixture. The final
concentrations were 50, 40, 20, 10 and 5 and 0.5 % for
each sample (Fig. 1). The sample numbers (1–10 in Fig. 1)
are used throughout the manuscript to refer to specific
mixture/dilution sample types.
Life technologies openArray assay
Standard Human TaqMan OpenArray Human
MicroRNA Panel, QuantStudioTM 12K flex chips (part
number 4470187) and other necessary reagents were pro-
vided by Life Technologies for this experiment. This panel
contains 754 human miRNA sequences from miRBase
v14 which have all been previously functionally validated
with miRNA artificial templates. For conversion of nota-
tion from miRBase v14 style to current miRNA style,
the webtool miRiadne can be used [16]. The specially
prepared post-pre-amp dilution mixtures were added to
the sample plates and then loaded onto the chips using
the Accufill robot following the standard protocols (Life
Technologies part number 4461306 Rev. B). A modified
MicroRNA .edt file, provided by Life Technologies, was
used to extend the cycles from the standard 40 to 46
cycles. This was done to make sure all amplifications went
to completion, as the authors noted that some microRNA
amplicons had not reached their maximal intensity at 40
cycles, causing a slight left shift to lower Crt values in
prior experiments. The additional cycles do not increase
the detection limit of the system. Three samples on one
chip (the first replicate from sample types 1, 3, and 9)
Fig. 1 Two RNA pools were formed by blending two tissues each: (A)
kidney and placenta and (B) skeletal muscle and brain. These pools
were combined in different mixtures and dilutions to form the 10
sample types shown here. Gene expression in each sample type was
assessed in quadruplicate (for a total of 40 samples) using the Life
Technologies OpenArray platform modified to perform 46
amplification cycles
were run using the standard MicroRNA .edt file provided
with the instrument, due to human error. This did not
have a noticeable effect on the expression estimates from
any of the algorithms. Additional information on the
TaqMan OpenArray MicroRNA Panels can be found
in the technical manual (Additional file 6).
Expression estimation algorithms
There are a wide variety of algorithms available to estimate
expression from qPCR amplification curves. To facilitate
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comparisons between these algorithms, we have applied
many of these algorithms to our benchmark data set.
The resulting expression estimates and quality scores are
available as data objects in themiRcomp package.
Specifically, we provide expression estimates from the
following methods:
• LifeTech ExpressionSuite
• 4 parameter sigmoidal model (b4)
• 5 parameter sigmoidal model (b5)
• 4 parameter log sigmoidal model (l4)
• 5 parameter log sigmoidal model (l5)
• Linear exponential model (linexp)
Additionally, the raw amplification data are available in
the miRcompData package allowing researchers to eas-
ily generate expression estimates using other current or
future algorithms.
Statistical assessments
The primary goal of the mixture/dilution experiment
described above is to provide a benchmark data set with
which to assess the performance of methods that esti-
mate miRNA expression from qPCR amplification curves.
Specifically, we propose assessments of accuracy, pre-
cision, data quality, titration response, limit of detec-
tion, and number of complete features. Each of these is
described in detail below. To avoid any confusion due to
naming conventions (expression estimates from amplifi-
cation curves have been called Ct values, Crt values, and
Cq values to name a few), we refer to the reported values
as expression estimates or simply expression.
Quality scores
When estimating expression from amplification data, it
is crucial for methods to provide both an expression
estimate and a corresponding quality score. These qual-
ity scores are often used to filter, flag, or down-weight
poor quality expression estimates in subsequent analyses.
The qualityAssessment function in themiRcomp package
allows one to examine the relationship between quality
scores and expression estimates, the distribution of qual-
ity scores across samples, and the relationship between
quality scores from two different methods.
Expression comparison
When comparing two methods, a natural starting point
is to compare the expression estimates produced by
each method. By examining the features and samples for
which expression estimates differ substantially, one can
better understand the strengths and limitations of each
method. The expressionComp function in the miRcomp
package allows one to examine the relationship between
expression estimates produced by two different methods.
Feature/sample combinations for which the expression
estimates differ by more than a given threshold are flagged
for further investigation.
Complete features
A measure of the amount of readily usable data pro-
duced by a method is the number of complete features
(here miRNAs). Complete features are defined as detected
(non-NA expression estimate) and of good quality (above
a given threshold) across all samples in a given experi-
ment. The completeFeatures function allows one to assess
a single method or compare two methods.
Limit of detection
The limit of detection is an estimate of the smallest sig-
nal that can be reliably measured. We propose assessing
the limit of detection in two ways: (1) examining the dis-
tribution of average observed expression stratified by the
proportion of values within a set of replicates that are
good quality, and (2) comparing the average observed vs
expected expression in the two low input sample types (9
& 10). The expected expression for both low input sam-
ple types (9 &10) can be calculated based on the pure
sample types (1 & 5) or, in the case of the 0.01/0.01 dilu-
tion (sample type 10), it can be calculated based on the
expression in the 0.1/0.1 dilution (sample type 9). Visual
representations of these comparisons are produced by the
limitOfDetection function.
The limitOfDetection function also reports several
potential limits of detection based on each of the following
comparisons:
1. Average observed expression in the 0.1/0.1 dilution
samples (sample type 9) vs expected expression based
on the pure samples (sample types 1 & 5).
2. Average observed expression in the 0.01/0.01 dilution
samples (sample type 10) vs expected expression
based on the pure samples (sample types 1 & 5).
3. Average observed expression in the 0.01/0.01 dilution
samples (sample type 10) vs expected expression
based on the 0.1/0.1 dilution samples (sample type 9).
For each of these comparisons, we calculate the dif-
ference between the observed and expected expression
estimates. To assess the limit of detection, we compute
the expression threshold such that the median difference
(between observed and expected) of all features exceeding
that threshold is equal to a predetermined tolerance. The
limitOfDetection returns these potential limits of detec-
tion for each comparison and three tolerances (0.5, 0.75,
and 1.00).
Titration response
The titration response is defined as the ability of a method
to produce monotone increasing expression estimates
in response to increasing amounts of input RNA. We
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consider sample types 2–4 and 6–8 as two separate titra-
tion series. In each of these series, onemixture component
is held constant at 80 μl and the other is doubled twice
from 16 μl to 32 μl to 64 μl. Because this response will
depend heavily on the underlying expression of a given
feature in each mixture component, the titration response
is stratified by the difference in expression between the
component being titrated and the component being held
constant. For example, in the sample type 2–4 titration
series, mixture component A is held constant and mix-
ture component B is titrated. To assess the difference in
expression between mixture components A and B, we use
the expression estimates in the pure sample types: sample
type 1 (pure A) and sample type 5 (pure B).
Accuracy
To assess accuracy, we calculate the signal detect slope,
defined as the slope of the regression line of observed
expression on expected expression, for the two titration
series (sample types 2–4 &6–8). The ideal signal detect
slope is one, representing agreement between observed
and expected expression. The signal detect slopes are
stratified by pure sample expression. A signal detect slope
captures the average relationship between observed and
expected expression; however, some features may perform
well on average but be highly variable. In the plots pro-
duced, features are displayed in grey if the signal detect
slope is not statistically significantly different from zero
(p-value < 0.05). As such, a grey point corresponding to
a signal detect slope well above zero represents a particu-
larly noisy (large residual variance) response.
Precision
To assess precision, we calculate both the within-replicate
standard deviation and coefficient of variation (the
within-replicate standard deviation divided by the within-
replicate mean). Both statistics are calculated for each set
of replicates (unique feature/sample type combinations)
that are of acceptable quality. For both summaries, the
values are stratified by the average observed expression.
Software
Software implementing the assessments described in this
manuscript was written in the open-source statistical lan-
guage R (v3.2.1) [14]. The R software package,miRcomp,
and the R data package, miRcompData, are available as
part of the Bioconductor project [15] (v3.2 and later),
a collaborative effort to develop software for computa-
tional biology and bioinformatics. In addition to the pri-
mary functionality described above, the miRcomp pack-
age containsmany additional options for customizable use
of these assessment functions. These are described in the
miRcomp package vignette (included here as Additional
file 1).
Results
In the following, we compare two methods to generate
expression estimates and quality scores from raw miRNA
qPCR amplification data. The first method is an algo-
rithm developed by Life Technologies and implemented in
the ExpressionSuite software package. This software pack-
age produces estimates of expression (called Crt values)
and a measure of quality (called the AmpScore). The sec-
ond method is a four-parameter log-sigmoid curve-fitting
algorithm [17] implemented as the default method in the
qpcR R package [18] and referred to in this manuscript
as simply qpcR. This open-source R package produces
expression estimates by fitting a four parameter log sig-
moidal curve to the amplification data and computing the
point at which the second derivative of this curve is max-
imized (cpD2 method) [19] and a measure of quality (the
R2 from the model fit).
Four additional algorithms (see Methods) were applied
to the benchmark data set, and the resulting expression
estimates and quality scores are available in themiRcomp
R package. For clarity of presentation in this manuscript,
we will focus on comparing two widely-used algorithms,
the default algorithms from Life Technologies and the
qpcR R package, in the following results.
Quality assessment
Given the interdependence between the expression esti-
mates and quality scores produced by a method, we begin
by examining this relationship for eachmethod (Fig. 2). As
one might expect, quality scores decrease as the expres-
sion estimates increase (recall that for qPCR based tech-
nologies, a higher expression value corresponds to fewer
copies of the target transcript). Another feature of note is
that both methods occasionally fail to produce an expres-
sion estimate (denoted as NA in Fig. 2). However, while
the qpcRmethod assigns all of these values fairly low qual-
ity (Fig. 2b), the Life Technologies method produces a
substantial number of NA expression estimates with high
quality scores (Fig. 2a).
When comparing two methods, it is also interesting to
examine the relationship between the quality scores pro-
duced by each method (Fig. 3). Examination of this figure
highlights regions of consensus high quality (upper right)
and consensus low quality (lower left) as well as regions of
disagreement between the methods (upper left and lower
right). While there are relatively few data points that are
estimated with a high quality AmpScore and low quality
R2, there are a substantial number of high quality R2 and
low quality AmpScore data points.
Taken together, Figs. 2 & 3 suggest quality thresholds
of AmpScore = 1.25 and R2 = 0.99. While we will
use these thresholds throughout the remainder of this
manuscript, all functions in the miRcomp package allow
the user to set their own quality thresholds. Furthermore,
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Fig. 2 Relationship between quality and expression. For both data sets, a measure of data quality, (a) Life Technologies (LifeTech) AmpScore or (b)
qpcR R-squared, is plotted against the corresponding expression estimates. The qpcR R-squared values are plotted on the complementary log-log
scale to improve visibility in the region of interest. Each point represents a single expression measurement and corresponding quality measure for a
unique miRNA/sample combination. Two-dimensional scatter-plot smoothing is used to avoid over-plotting and convey the distribution of points

















Fig. 3 Comparison of quality scores. A direct comparison between
the quality scores: Life Technologies (LifeTech) AmpScore and qpcR
R-squared. The vertical dashed line represents the recommended
AmpScore threshold of 1.25. The horizontal dashed line represents a
potential R-squared threshold chosen by examination of this figure.
Each point represents the quality values for a unique miRNA/sample
combination. Two-dimensional scatter-plot smoothing is used to
avoid over-plotting and convey the distribution of points across the
plotting region
for many functions, one can compare results from a single
method using two different quality thresholds to exam-
ine the effect of changing the quality threshold on each
assessment. Lastly, when comparing twomethods, we typ-
ically restrict the assessment to data considered to be good
quality by both methods. This provides the most direct
comparison between the expression estimates produced
by the two methods; however, for many of these assess-
ments, themiRcomp package allows one to perform these
comparisons using each method’s own quality assessment
independently.
Expression comparison
When comparing two methods, it is also interesting to
examine the relationship between the expression esti-
mates produced by each method (Fig. 4a). Overall, the
expression estimates produced by the Life Technologies
and qpcR methods are quite similar; however, one fea-
ture/sample shows a substantial difference betweenmeth-
ods (miR-155 in sample KW10:2). One can investigate this
difference further by examining the raw amplification data
provided in themiRcompData package. For comparison,
we selected a feature from the same sample for which
the two methods were approximate agreement (miR-29a
in sample KW10:2). The amplification curve for miR-155
(Fig. 4b) shows the probable cause of the discrepency
between expression estimates – the amplification curve is
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Fig. 4 Comparison of expression estimates. a Expression estimates from Life Technologies (LifeTech) method and the default qpcR method are
plotted against one another. The miRNA/sample combination in which the expression estimates differ most (miR-155; KW10:2) is represented by a
black dot. An miRNA/sample combination in which the expression estimates roughly agree (miR-29a/KW10:2) is represented by a red dot. b & c The
amplification curve data (Rn vs cycle) for bmiR-155 or cmiR-29a in sample KW10:2 with expression estimates for each method denote by vertical
lines. Note that the amplification curve is still increasing at cycle 46 for miR-155 whereas for miR-29a is has leveled off
still increasing at the maximum observed cycle. In con-
trast, the amplification curve for miR-29a (Fig. 4c) has
clearly reached a plateau before the maximum cycle. This
results in expression estimates that are fairly similar across
methods.
Complete features
Given the difficulty in measuring the expression of many
miRNAs, we examine the number of complete features
(good quality across all 40 samples), partial features
(good quality in at least one but not all samples), and
absent features (poor quality in all 40 samples). Exam-
ining the number of features that fall into each of these
Table 1 Complete feature assessment
qpcR method
Complete Partial Absent
LifeTech Complete 162 3 0
Method Partial 87 288 0
Absent 2 109 103
Complete features are ones that are detected (non-NA expression estimate) and
have good quality across all 40 samples. Partial features are those that are detected
and good quality in at least one (but not all) of the 40 samples. Absent features are
those that are not detected or of poor quality in all 40 samples. These values are
used to compare the performance of the Life Technologies (LifeTech) and qpcR
algorithms
categories for each method (Table 1) provides a straight-
forward assessment of the amount of easily usable data
produced by each method. Of the 754 features in these
data, there are 165 complete features using the Life Tech-
nologies method and 251 complete features using the
qpcR method; however, this may simply be a result of
the choice of quality threshold. Of note, there are 162
complete features in common between both methods
and 103 features that are considered absent by both
methods. The latter may represent miRNAs that are not
expressed in any of the four tissues included in these
data.
Limit of detection
Next, we examine the limit of detection for a given
method. While this is related to the previous assessment
of complete features, here the focus is on determining the
minimum signal that can be reliably detected. The first
assessment compares the difference between observed
and expected expression vs the expected expression based
on three different comparisons (Fig. 5). One can visually
assess the limit of detection by identifying the expected
expression value (x-axis) at which the expression differ-
ence (y-axis) begins to diverge from zero and the data
are of increasingly poor quality. A quantitative version
of this approach is described in the Methods Section.
Potential limits of detection for each comparison and each
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Fig. 5 Limit of Detection MA-plots. To assess the limit of detection for a given method (Life Technologies a-c; qpcR d-f), we plot the difference
between the observed and expected average expression vs the expected expression for each feature in the two low input sample types (either the
0.1/0.1 or 0.01/0.01 dilution samples). The expected expression is calculated using either the pure sample expression (a, b, d, & e) or the 0.1/0.1
dilution expression (c & f). Each point represents an miRNA in the sample type of interest. Features for which all four data points are of good quality
are shown in black; other features are shown in red with the proportion of poor quality values for each feature denoted by plotting symbol. One can
visually assess the limit of detect by the expected expression value (x-axis) at which the difference between observed and expected expression
begins to differ substantially from zero and the proportion of poor quality values increases
tolerance are shown in Table 2. In general, the three com-
parisons produce similar limits of detection for a given
tolerance.
An alternative approach to assess the limit of detec-
tion is to examine the distribution of average observed
expression among replicates (unique feature/sample type
combinations) stratified by the proportion of poor quality
(Fig. 6). This allows one to easily see that higher expression
values result in increasing amounts of poor quality data;
however, for both methods, there is substantial overlap
between the distributions.
Titration response
We now turn to assessments of the expression estimates
themselves. For both methods, we calculated the pro-
portion of features that show a titration response (see
Methods for definition) for each titration series (Table 3).
We also stratify these results by the difference in pure
sample expression between the mixture component being
titrated and the component being held constant (Fig. 7).
As one might expect, if an miRNA is far less abun-
dant in the component being titrated than in the com-
ponent being held constant, it is difficult to detect a
titration response for this miRNA. If an miRNA is far
more abundant in the component being titrated than
in the component being held constant, it is relatively
easy to detect a titration response for this miRNA.
While both methods perform fairly well when the
features are expressed higher in the titrating compo-
nent (x-axis value > 0), the Life Technologies method
appears to perform slightly better for features expressed
higher in the component being held constant; how-
ever, neither method performs particularly well for such
features.
Accuracy
Related to the titration response is the accuracy of
the expression estimates. Rather than simply requiring
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Table 2 Potential limits of detection
LifeTech method
0.1/0.1 vs pure 0.01/0.01 vs pure 0.01/0.01 vs 0.1/0.1
0.50 27.6 26.8 26.3
0.75 28.9 28.4 28.4
1.00 29.1 29.0 29.2
qpcR Method
0.1/0.1 vs pure 0.01/0.01 vs pure 0.01/0.01 vs 0.1/0.1
0.50 26.9 25.8 25.3
0.75 29.2 28.3 28.6
1.00 30.1 29.3 29.9
Here we report three potential limits of detection based on the three assessments
(0.1/0.1 vs pure, 0.01/0.01 vs pure, and 0.01/0.01 vs 0.1/0.1). Limits of detection are
reported separately for the Life Technologies (LifeTech) and qpcR algorithms.
Columns correspond to the different assessments, and rows correspond to the
median difference between the observed and expected values. The values in the
matrix are the expected expression values such that the median absolute difference
for all larger expected expression values is approximately equal to the threshold for
that row. For example, consider the Life Technologies method, if we focus on the
0.1/0.1 vs 0.01/0.01 comparison (column 3) and set a median average difference
threshold of less than 1.00 (row 3), our estimate of the limit of detection is
approximately 29.2
monotone increasing expression estimates in response to
increasing input RNA, here we are interested in the actual
magnitude of the increase in expression. Specifically, to
assess accuracy, we calculate the signal detect slope,
defined as the slope of the regression line of observed
expression on expected expression. We stratify the sig-
nal detect slopes into three equally sized bins to highlight
the dependence on the underlying difference in expression
noted in the previous subsection. Similar to the results
seen in Fig. 7, accuracy is better for features with higher
relative expression in the titrating component (Fig. 8). For
each of the bins shown in Fig. 8, we can summarize the
accuracy by computing robust measures of center and
spread – median and median absolute deviation (MAD) –
of the signal detect slopes (Table 4). The qpcR method
appears to have slightly better accuracy, although this is
not significant.
Precision
Finally, we consider a measure of precision, the within-
replicate coefficient of variation. Here, replicates are
defined as each unique feature/sample type combination
consisting of four data points each. The data are divided
into three bins of equal size based on the average expres-
sion of each replicate (Fig. 9). Both methods appear to
have comparable precision.
Performance of other algorithms
To this point, we have focused on assessing two algo-
rithms to demonstrate the functionality of the miRcomp
R/Bioconductor package. However, we also applied four
additional algorithms (see Methods) to this benchmark
data set. The resulting expression estimates and qual-
ity scores are available in the miRcomp R package.
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B
Fig. 6 Limit of Detection Boxplots. To further examine the limit of detection, we examine boxplots of average observed expression stratified by the
proportion of poor quality data points. Below each box, we also report the number of unique feature/sample type combinations each box contains.
Results from the Life Technologies method are shown in panel a; results from the qpcR method are shown in panel b
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Table 3 Titration response
LifeTech:A qpcR:A LifeTech:B qpcR:B
Titration response 96 84 163 161
Non-response 108 120 41 43
This table displays the number of features that show a titration response
(monotone increasing expression as the input RNA increases) for each method, Life
Technologies (LifeTech) and qpcR, and each titration series (sample types 2–4 and
6–8). Here A and B refer to the mixture component being titrated: placenta & kidney
(A) or skeletal muscle & brain (B)
Performance assessments comparing all six algorithms are
shown in Additional file 7: Figures S2–S7.
The relationship between expression estimates and
quality scores was fairly similar across methods with the 5
parameter log sigmodial method producing slightly better
quality scores and the linear exponential method produc-
ing overall lower quality scores (Additional file 7: Figure
S2). The limit of detection was roughly 30 for all six algo-
rithms, although the limit of detection appears slightly
lower for the Life Technologies and linear exponential
methods (Additional file 7: Figures S3 & S4). The Life



























Fig. 7 Titration Response. To examine the titration response, we plot
the proportion of features that showmonotone increasing expression
as the amount of input RNA increases stratified by the difference in
expression between the sample being titrated and the sample being
held constant. Here we use samples 2–4 and 6–8 as two separate
titration series. To assess the difference in expression betweenmixture
components A and B, we use the expression estimates in the pure
sample types: sample type 1 (pure A) and sample type 5 (pure B). Each
point represents an average over the miRNAs falling within a given
bin, where bins are defined based on the observed difference in pure
sample expression (x-axis). The The Life Technologies (LifeTech) values
are plotted with solid circles; the qpcR values with open squares
formed somewhat better in terms of titration response,
while the linear exponential method performed signif-
icantly worse (Additional file 7: Figure S5). The linear
exponential and 5 parameter log sigmoid methods had the
best accuracy on average, but they also had themost varia-
tion in accuracy (Additional file 7: Figure S6). All methods
performed better when the target transcript was highly
expressed. The Life Technologiesmethod had consistently
the best precision and the 5 parameter log sigmoidal
method had consistently the worst precision (Additional
file 7: Figure S7).
Discussion
In the previous section, we focused on assessing two algo-
rithms to demonstrate the functionality of the miRcomp
R/Bioconductor package. Additionally, we evaluated the
performance of four other algorithms. In summary, the
4-parameter and 5-parameter sigmodial and log-
sigmodial algorithms performed similarly, with the
5-parameter log-sigmoidal achieving slightly better accu-
racy by sacrificing some precision. In contrast the Life
Technologies method appears to have sacrificed a bit of
accuracy to achieve better precision. The linear expo-
nential algorithm performed significantly worse than the
other five methods.
However, the primary purpose of this work is to
facilitate the development of new expression estima-
tion algorithms by allowing researchers to assess their
own method(s). The benchmark data set, described in
the Methods section and provided in the miRcomp-
Data R/Bioconductor package, provides a rich resource
for novel methods development. One can use the assess-
ment functions in the miRcomp package to examine
the effect of higher or lower quality thresholds for a
currently available algorithm. We anticipate that these
packages will facilitate the comparison of competing
algorithms and guide the selection of those most suit-
able for a specific experiment. Furthermore, we antic-
ipate that the development of open-source software to
estimate expression from the raw amplification data
will lead to increased integration between expression
estimation procedures and subsequent statistical anal-
yses, often performed with R/Bioconductor software
packages.
Software to estimate expression from amplification data
are implemented across a wide variety of operating sys-
tems (e.g. Windows, Mac OS, and Unix/Linx) and pro-
gramming languages (e.g. R, Python, Perl, and SAS) [20].
As there is currently no standard data structure for raw
qPCR amplification data, we store the raw data in a
simple table that can be easily exported for the miRcom-
pData package and converted into formats required by
other expression estimation software. While the assess-
ments described in this manuscript are implemented in R,
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Fig. 8 Accuracy Assessment. To assess accuracy, we calculate the signal detect slope: the slope of the regression line of observed expression on
expected expression for both the Life Technologies (LifeTech) and qpcR algorithms. The ideal signal detect slope is one, representing agreement
between observed and expected expression. The signal detect slopes are stratified by pure sample expression. Each point represents an miRNA.
Points in the figures below are grey if the signal detect slope is not statistically signficantly different from zero. As such, a grey point corresponding
to a signal detect slope well above zero represents a particularly noisy (large residual variance) response
the assessment functions accept simple matrices as input,
which should be easy to create from the output of any
other software package.
The assessment strategy proposed in this manuscript
is based on a mixture/dilution experimental design. An
alternative strategy would have been to spike-in known
amounts of several miRNAs. Assessing accuracy for
genomic technologies presents a challenge because the
correct outcome for a given measurement must be known
a priori. Spike-in experiments represent a natural way
Table 4 Accuracy assessment
LifeTech method
Low Medium High
Bin (−0.0983,0.916] (0.916,1.95] (1.95,11.7]
Median 0.85 0.91 0.90
MAD 0.32 0.19 0.14
qpcR method
Low Medium High
Bin (−0.095,0.964] (0.964,2.07] (2.07,12]
Median 0.86 0.95 0.95
MAD 0.34 0.20 0.15
For each of the bins shown in Fig. 8, robust estimates of the center (median) and
spread (MAD) of the signal detect slopes are reported for each method, Life
Technologies (LifeTech) and qpcR
to accomplish this by comparing the nominal spike-in
concentrations with the observed expression estimates.
This is crucial to assess the accuracy of absolute expres-
sion estimates. However, performance assessments based
on spike-in data depend strongly on the chosen spike-
in concentrations [21, 22]. One must select spike-ins
that span the entire dynamic range of observed expres-
sion, are unexpressed in all biological samples being
analyzed, and are measured by the technology under
consideration.
In a mixture/dilution experiment, the focus is on rel-
ative rather than absolute expression. While the abso-
lute expression of a given feature is unknown, the
relative expression is known. Therefore, in the assess-
ments proposed in this manuscript, we have focused
on the ability of various methods to accurately mea-
sure relative expression. Additionally, mixture/dilution
experiments are inherently more realistic with respect
to the dynamic range of observed expression levels by
using mixtures of two biologically distinct RNA pools at
varying proportions. Such a mixture/dilution approach
allows one to characterize performance of assays across
the full spectrum of expression, which is necessary to
assess the performance of any analytic strategy. While
one is restricted to assessments of relative expression,
this corresponds to the standard use of qPCR expres-
sion assays – to measure differential rather than absolute
expression.
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Fig. 9 Precision Assessment. To assess precision, we calculate the within-replicate coefficient of variation, calculated as the within-replicate standard
deviation divided by the within-replicate mean, for both the Life Technologies (LifeTech) and qpcR algorithms. These are calculated for each set of
replicates (unique feature/sample type combination) that are of good quality and stratified by the observed expression
Conclusions
In this manuscript, we present a benchmark data set
and software to assess the performance of methods that
estimate expression from raw data on the Life Tech-
nologies OpenArray microRNA platform. The raw
data and software packages, miRcomp and miRcom-
pData, are open-source and freely available as part
of the Bioconductor project. We believe that the data
and assessment software will facilitate the develop of
novel methods for quantification of microRNA expres-
sion from the Life Technologies OpenArray platform.
Using these packages, we assessed the performance of
six expression estimation algorithms. The 5-parameter
log-sigmodial algorithm had the best accuracy; the Life
Technologies method had the best titration response and
precision.
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